AI assistant
IMUGENE LIMITED — Board/Management Information 2026
Jan 1, 2026
65124_rns_2026-01-01_211d2f53-850f-4820-9815-85246d40330d.pdf
Board/Management Information
Open in viewerOpens in your device viewer
==> picture [177 x 31] intentionally omitted <==
ASX Announcement
Executive Update
SYDNEY, Australia, 2 January 2026: Imugene Limited (ASX:IMU), a clinical-stage immuno-oncology company, announces that Dr. Bradley Glover has resigned from his position as a Chief Operating Officer of Imugene to focus on his other business interests.
The Company will manage the transition of responsibilities with no impact on business operations or ongoing programs.
Commenting on the transition, Dr Glover said “It has been a true privilege to serve as COO of Imugene and to work alongside such a talented and committed team advancing innovative oncology programs. I am proud of what we have achieved together,
particularly the progress of azer-cel, and I wish the Company continued success as it moves into its next phase.”
The Board and management extend their sincere gratitude to Dr Glover for his outstanding service and contributions to Imugene.
==> picture [527 x 31] intentionally omitted <==
For more information please contact:
Leslie Chong Managing Director and Chief Executive Officer
General Investor Enquiries
Media Enquiries
Connect with us on LinkedIn @Imugene Limited Follow us on Twitter @TeamImugene Watch us on YouTube @ImugeneLimited
IMUGENE LIMITED ACN 009 179 551
WWW.IMUGENE.COM
==> picture [42 x 42] intentionally omitted <==
About Imugene (ASX:IMU)
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.
Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies may become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.
Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.
IMUGENE LIMITED ACN 009 179 551
2